- GILD -0.72%
Avenzo and Gilead partner for breast cancer combination regimen trial
Yahoo Finance · 22 hours ago
Open | 79.70 |
High | 80.00 |
Low | 78.73 |
Mkt Cap | 98.52B |
P/E (TTM) | 96.50 |
Div & Yield | 3.08 & 3.89% |
Prev. Close | 79.70 |
52 Wk. Low | 62.07 |
52 Wk. High | 87.87 |
Related stocks
American company
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Wikipedia
(USD) | Q2 2024 | Y/Y |
---|---|---|
Revenue | 6.95B | 5.40% ▲ |
Net Income | 1.61B | 54.50% ▲ |
Diluted EPS | 2.01 | 55.40% ▲ |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q3 2024 | $1.59 | - |
Q2 2024 | $1.60 | $2.01 |
Q1 2024 | -$1.49 | -$1.32 |
S&P FuturesES=F | 5,537.25+7.25 (+0.13%) |
Dow FuturesYM=F | 41,109.00+58.00 (+0.14%) |
Nasdaq FuturesNQ=F | 18,977.00+14.50 (+0.08%) |
23.01-1.88% | |
32.39-11.60% | |
29.38-17.47% |